Special Issue "Drug/Radiation Resistance in Cancer Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 September 2015)
Dr. Dong-Hua Yang
Department of Pharmaceutical Sciences, St. John's University, Queens, USA
Interests: Biomarkers; Anti-Cancer Drugs; Cancer Chemotherapy; Cancer Biology; Developmental Biology
The phenomenon of drug and/or radiation resistance has attenuated the efficacy of chemotherapeutic agents as well as radiotherapy, and reduced the possibility of successful cancer treatment. Progress has been made in recent years in understanding many of the resistant mechanisms, and of methods to overcome resistance. Scientists have elucidated that Multidrug Resistance (MDR) is a major obstacle to cancer treatment, which can be induced by anticancer drugs and ionizing radiation. The most common mechanisms that produce MDR in cancer cells include: (1) altered cell cycle check points; (2) induction of emergency response genes; (3) enhanced DNA repair; (4) alterations in membrane proteins or lipids; (5) compartmentalization; (6) inhibition of apoptosis; (7) altered drug targets; (8) decreased uptake; and (9) increased efflux of drugs by ATP-binding cassette (ABC) transporters.
Among the ABC transporters family, ABCB1, ABCG2, and ABCCs are the primary contributors of MDR in cancer cells. Interestingly, the overexpression of ABCB1 has been associated with various cancers, such as gastrointestinal stromal tumor (GIST), non-small cell lung cancer (NSCLC), and ovarian and thyroid cancers. It has also been shown that increased resistance to both chemotherapy and radiation is a feature of Cancer Stem-like Cells (CSCs): the subset of cells within a tumor that have the ability to drive tumor re-growth or to initiate a metastatic lesion. ABCG2 is implicated as a CSC biomarker in diverse malignancies.
This Special Issue will cover subjects related to recent progress on drug and radiation resistance in cancer therapy. It will increase our understanding of the clinical efficacy and challenges of chemotherapy and radiotherapy in a variety of cancers.
Prof. Dr. Zhe-Sheng (Jason) Chen
Dr. Dong-Hua (Hana) Yang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- multidrug resistance
- ABC transporters
- cancer stem-like cells